Pharmaceutical composition containing mesenchymal stem cells and application of pharmaceutical composition in weight loss and lipid reduction

Through the combination of mesenchymal stem cells and ASGR1 protein monoclonal antibody 4, the limitations and side effects of existing weight loss and lipid reduction methods are solved, safe and efficient regulation of fat metabolism and blood lipid level control are achieved, and the risk of cardiovascular disease is reduced.

CN119039442AInactive Publication Date: 2024-11-29GUANGDONG ZELANG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411238630.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing methods for weight loss and lipid reduction have limitations and side effects, and lack an effective and safe pharmaceutical composition to utilize the weight loss and lipid reduction potential of mesenchymal stem cells.

Method used

A pharmaceutical composition is developed, including an effective amount of mesenchymal stem cells and ASGR1 protein monoclonal antibody 4, for regulating lipid metabolism, inhibiting adipocyte production, and reducing obesity-related inflammatory responses through immune regulation.

Benefits of technology

The composition promotes the metabolism of adipose tissue, accelerates fat decomposition, regulates blood lipid levels, reduces the risk of cardiovascular disease, and is safe and has fewer side effects, providing a new direction for weight loss and lipid reduction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119039442A_ABST
    Figure CN119039442A_ABST
Patent Text Reader

Abstract

On one hand, the invention discloses an ASGR1 protein monoclonal antibody, the monoclonal antibody is a monoclonal antibody 4, and the sequences of a heavy chain variable region and a light chain variable region of the monoclonal antibody 4 are respectively shown as SEQ ID NO. 1 and SEQ ID NO. 2. The invention also discloses a pharmaceutical composition for losing weight and lowering lipid. The pharmaceutical composition comprises an effective amount of mesenchymal stem cells and an effective amount of the ASGR1 protein monoclonal antibody 4. The pharmaceutical composition for losing weight and lowering lipid prepared by the invention has the effects of promoting metabolism of adipose tissues and accelerating lipolysis; the blood fat level is regulated, and the risk of cardiovascular diseases is reduced; the inflammatory response related to obesity is reduced through the immune regulation effect; the safety is high and the side effect is small. Therefore, the pharmaceutical composition for losing weight and lowering lipid provides a new direction for losing weight and lowering lipid.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of stem cells, and in particular to a pharmaceutical composition containing mesenchymal stem cells and application thereof in weight loss and lipid reduction. Background Art

[0002] With the improvement of living standards and changes in lifestyle, obesity and hyperlipidemia have become increasingly serious health problems worldwide. Existing methods for weight loss and lipid reduction mainly include drug therapy, surgical treatment and diet control. However, these methods have certain limitations and side effects to a greater or lesser extent. Therefore, it is particularly important to find an effective and safe method for weight loss and lipid reduction.

[0003] Mesenchymal stem cells (MSC) are multipotent stem cells with the potential to differentiate into multiple cell types. Recent studies have found that MSC has a significant effect on weight loss and lipid reduction. MSC mainly secretes multiple cytokines, regulates lipid metabolism, and inhibits adipocyte production, thereby achieving the purpose of weight loss and lipid reduction. However, there is currently no MSC as a pharmaceutical composition for weight loss and lipid reduction. Summary of the invention

[0004] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells and its application in weight loss and lipid reduction.

[0005] Therefore, the present invention discloses, on one hand, a monoclonal antibody against ASGR1 protein, wherein the monoclonal antibody is monoclonal antibody 4, and the sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody 4 are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively.

[0006] In another aspect, the present invention further discloses a pharmaceutical composition for weight loss and lipid reduction, wherein the pharmaceutical composition comprises an effective amount of mesenchymal stem cells and an effective amount of the ASGR1 protein monoclonal antibody 4.

[0007] Preferably, the content of mesenchymal stem cells in the pharmaceutical composition of the present invention is 5×10 5 pcs / 0.2ml.

[0008] Preferably, the content of ASGR1 protein monoclonal antibody 4 in the pharmaceutical composition of the present invention is 50 μg / 0.2 ml.

[0009] In another aspect, the present invention also discloses a use of the monoclonal antibody 4 in preparing a weight loss and lipid-lowering pharmaceutical composition.

[0010] The pharmaceutical composition for weight loss and lipid reduction prepared by the present invention has the functions of promoting the metabolism of adipose tissue and accelerating fat decomposition; regulating blood lipid levels and reducing the risk of cardiovascular diseases; reducing obesity-related inflammatory reactions through immunomodulatory effects; and having high safety and low side effects. Therefore, the pharmaceutical composition for weight loss and lipid reduction prepared by the present invention provides a new direction for weight loss and lipid reduction. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figure 1 SDS-PAGE detection result diagram of monoclonal antibody 4, where 1 is monoclonal antibody 4. DETAILED DESCRIPTION

[0012] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0013] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. The culture medium used for the isolation and culture of human mesenchymal stem cells was purchased from Merck. Unless otherwise specified, the reagents and materials used in the following examples were commercially available.

[0014] Example 1: Isolation and culture of mesenchymal stem cells

[0015] Open the fat collection bottle (from a hospital in Guangdong) in a biosafety cabinet, transfer the fat to a culture bottle, add PBS, rinse and fully chop into a paste, add 125U / mL type I collagenase, and place in a shaker at 37°C for 30 minutes for digestion.

[0016] After digestion is terminated, centrifuge (900g, 10 minutes), remove the supernatant and undigested fat, resuspend the cell pellet with a small amount of culture medium, dissolve the remaining red blood cells with 0.16mol / L ammonium chloride, filter the collected cell suspension through a 200-mesh copper mesh, and obtain mononuclear cells after centrifugation. After counting, add culture medium (generally DMEM culture medium containing 10% FBS) for subculture to obtain adipose stem cells.

[0017] When the cells reach about 80% confluence, perform cell passage. Discard the culture medium, add 3-5ml trypsin-EDTA solution, and incubate in a 37℃ incubator for 3-5 minutes. After the cells are completely digested, add 5ml culture medium to the culture flask. Gently rotate the culture plate to mix the cell suspension. Transfer the dissociated cells to a 15ml offline tube, centrifuge at 500rpm for 5min, and carefully remove the supernatant. Add culture medium to a 15ml centrifuge tube to resuspend the cells. Count the cells and divide the cells into 10 according to the count results. 4 / cm 2 The cells are inoculated at a density of 100 μg / mL into a suitable culture flask containing culture medium, and when the cells reach a confluence of about 80%, the cells are passaged, expanded, or frozen for future use.

[0018] Example 2: Preparation of ASGR1 monoclonal antibody

[0019] ASGR1 (Asialoglycoprotein Receptor 1) is a specific protein receptor present on the liver cell membrane that can recognize and bind to asialoglycoproteins in the blood, "capture" them by mediating endocytosis and send them to the lysosomes in the cell for degradation. Loss-of-function mutations in the Asgr1 gene are associated with lower cholesterol levels and CVD risk [Nioi, P. et al. Variant ASGR1 associated with a reduced risk of coronary artery disease. N. Engl. J. Med. 374, 2131-2141 (2016).]. Subsequently, animal experimental data also supported that the loss of ASGR1 protein expression can reduce cholesterol levels in the blood [Xu, Y. et al. Hypomorphic ASGR1 modulates lipid homeostasis via INSIG1-mediated SREBP signaling suppression. JCI Insight 6, e147038 (2021).]. Therefore, inhibitors of ASGR1 may serve as an important target for inhibiting fat production.

[0020] Select 7-week-old BALB / c mice. Day 1: 100 μg ASGR1 protein (MCE, HY-P7610) + Freund's complete adjuvant, intraperitoneal injection 0.4 ml / mouse. Day 7: 100 μg ASGR1 protein + equal volume of incomplete adjuvant, intraperitoneal injection 0.4 ml / mouse. Day 12: 50 μg ASGR1 protein, intravenous injection 0.3 ml / mouse (for boosting). Day 15: 20 μg ASGR1 protein, intravenous injection 0.3 ml / mouse. Fusion is performed within 17-24 days.

[0021] B lymphocytes are fused with HGPRT-deficient myeloma cells, usually using the polyethylene glycol (PEG) method or the electrofusion method. Electrofusion is more efficient and causes less damage to cells. Use HAT medium to screen hybridoma cells. Myeloma cells cannot survive because they cannot synthesize DNA, and B cells can only survive for 7-10 days under in vitro conditions. Hybridoma cells can grow in HAT medium. Subclone screening is performed by the limiting dilution method. The hybridoma cell suspension is diluted several times and inoculated into a 96-well plate with no more than 1 cell per well. After culture, the antibodies in the supernatant of each well are detected by ELISA to select positive monoclonal clones.

[0022] Seven-week-old Balb / c mice were intraperitoneally injected with 0.5 ml of pristane per mouse. Seven days later, each mouse was injected with 1×10 hybridoma cells. 6 After 7 days, the mouse ascites was extracted and centrifuged at 1000r / min for 10 minutes at 2-8°C to collect the supernatant. The monoclonal antibody was purified using a ProteinG affinity chromatography column, and after quantitative packaging, it was stored below -70°C for later use. After this step, a better hybridoma cell line was screened, and on this basis, the corresponding monoclonal antibody was prepared, labeled as monoclonal antibody 4, and its SDS-PAGE test results are shown as follows: Figure 1 As shown, the purity can reach more than 95%.

[0023] The commercial mouse monoclonal antibody subtype identification ELISA kit was used to identify the subtypes of the heavy chain and light chain of the monoclonal antibody according to the instructions. After testing, the heavy chain subtype of monoclonal antibody 4 was IgG2, and the light chain was Kappa.

[0024] The antibody gene sequence was cloned using a method based on the RACE technology route. Hybridoma cells with good growth status were collected, and total RNA of hybridoma cells was obtained using a total RNA extraction kit. The mRNA was reverse transcribed into cDNA according to the operating method of Takara's SMARTer RACE instructions, and the full-length sequence of the target antibody was amplified. After sequencing and analysis, the sequences of the heavy chain variable region and light chain variable region of monoclonal antibody 4 were shown in SEQ ID NO.1 and SEQ ID NO.2, respectively, and the CDR sequence analysis results of monoclonal antibody 4 are shown in Table 1.

[0025] Table 1 CDR sequence analysis results of monoclonal antibody 4

[0026]

[0027] Example 3: Experiment on the therapeutic effect of the pharmaceutical composition on obesity in mice

[0028] 35 3-week-old male SPF-grade C57BL / 6J mice were selected, weighing about 15-17g. After one week of adaptive feeding, the mice were randomly divided into two groups, a "blank control group" and a "model group", with 5 mice in the blank control group and 30 mice in the model group. The control group was fed with ordinary feed, and the model group was fed with a high-fat diet with a fat energy supply ratio of 60%. The general condition of the animals was observed daily, and the body weight and fasting blood sugar were measured once every 2 weeks. After 20 weeks of feeding, the control group was normal, the fasting blood sugar of the model group was greater than 11mM, and cholesterol was significantly increased. The model group was randomly divided into 6 groups, 1 of which was the model control group, and 5 groups were treated with related drug compositions (as shown in Table 2).

[0029] Table 2 Composition of drug composition and treatment regimen

[0030]

[0031] The mice in the above groups after treatment were weighed 4 weeks after the first treatment, and the weight before treatment was subtracted to obtain the net weight gain during the entire treatment period. The results are shown in Table 3. Drug 1 has a certain effect, and drug 2 has a better effect than drug 3, but both are not as good as drug 1; drug 4 has the best effect, which is better than drug 5. And the monoclonal antibody 4 prepared by the present invention is worse than the commercial monoclonal antibody.

[0032] According to the above results, the mesenchymal stem cells prepared by the present invention and the monoclonal antibody 4 have good effects, and the combined effect of the two is even better. This shows that the monoclonal antibody 4 of the present invention has a good synergistic effect with the mesenchymal stem cells and can significantly improve the therapeutic effect of stem cells.

[0033] Table 3 Net weight gain of mice in each treatment group

[0034]

[0035] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. A monoclonal antibody against ASGR1 protein, characterized in that: The monoclonal antibody is monoclonal antibody 4, and the sequences of the heavy chain variable region and the light chain variable region of monoclonal antibody 4 are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively.

2. A pharmaceutical composition for weight loss and lipid reduction, characterized in that: The pharmaceutical composition comprises an effective amount of mesenchymal stem cells and an effective amount of the ASGR1 protein monoclonal antibody 4 according to claim 1.

3. The pharmaceutical composition according to claim 2, characterized in that The content of the mesenchymal stem cells is 5×10 5 pcs / 0.2ml.

4. The pharmaceutical composition according to claim 2, characterized in that The content of the ASGR1 protein monoclonal antibody 4 is 50 μg / 0.2 ml.

5. Use of the monoclonal antibody 4 according to claim 1 in preparing a weight loss and lipid-lowering pharmaceutical composition.